Ronac Mamtani, MD, MSCE
David J. Vaughn MD Associate Professor in GU Oncology
Attending Physician, Hematology-Oncology, Hospital of the University of Pennsylvania
Section Chief, GU Medical Oncology , University of Pennsylvania
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-308
3400 Civic Center Blvd
Philadelphia, PA 19147
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-308
3400 Civic Center Blvd
Philadelphia, PA 19147
Office: 2156627606
Fax: (215) 349-8551
Fax: (215) 349-8551
Email:
ronac.mamtani@uphs.upenn.edu
ronac.mamtani@uphs.upenn.edu
Education:
BS
Cornell University, 2002.
MD (Internal Medicine)
Stony Brook School of Medicine, 2006.
MS (Clinical Epidemiology)
University of Pennsylvania , 2012.
Permanent linkBS
Cornell University, 2002.
MD (Internal Medicine)
Stony Brook School of Medicine, 2006.
MS (Clinical Epidemiology)
University of Pennsylvania , 2012.
Selected Publications
Shen J, Linn KA, Clark AS, Mamtani R, Hubbard RA.: Missingness in Eligibility Criteria for Target Trial Emulation in EHR With Survival Outcomes. Stat Med 45, Apr 2026.Litt HK, Wodzinski A, Subramanian P, Donovan M, Vapiwala N, Parikh RB, Narayan V, Mei L, Takvorian SU, Balzer Haas N, Mistry R, and Mamtani R.: OncoEducate: A pilot study of generative AI to support patient education in GU cancer care. American Society of Clinical Oncology Genitourinary Cancers Symposium, San Fran, CA. 44(7): 713, Mar 2026 Notes: "Poster Presentation"
Galsky MD, Izadmehr S, Yu M, Curtis SD, Douville C, Popoli M, Ptak J, Dobbyn L, Silliman N, Chan KG, Dorff TB, Cetnar JP, O'Neil B, D'Souza A, Mamtani R, Kyriakopoulos CE, Brody R, Sadimin E, Mehrazin R, Chowell D, Sfakianos J, Daneshmand S, Pal SK, Bettegowda C, Kinzler KW, Papadopoulos N, Vogelstein B, Wang Y.: Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer. Proc Natl Acad Sci U S A 123: e2533449123, Feb 2026.
Squires P, Cook EE, Song Y, Wang CY, Zhang A, Seshasayee SM, Rogiers A, Li H, Mamtani R.: Treatment Patterns, Disease Recurrence, and Overall Survival in Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy: A Population-Level Claims-Based Analysis. Clin Genitourin Cancer Feb 2026.
Wang X, Long JB, Rothen J, Huang S, Soulos PR, Goldberg SB, Robinson TJ, Ma S, Mamtani R, Presley CJ, Wang SY, Kunst N, Gross CP, Dinan MA.: A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling. J Natl Compr Canc Netw 24: e257131, Feb 2026.
Chow RD, Sedhom R, Mamtani R.: Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer. JAMA Oncol Nov 2025.
Litt HK, Mamtani R, Chow RD.: Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction. Urol Oncol Nov 2025.
Kong AM, Andrean D, Khan S, Choi J, Mamtani R, Parikh R, Jaksa A, Campbell U.: Considerations for emulations of randomized controlled trials using real-world data: learnings from an emulation of MONALEESA-2. J Comp Eff Res Oct 2025.
Chow RD, Mamtani R.: Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma. Urol Oncol 43(10): 597, Oct 2025.
Meng Y, Zhang S, Aout M, Babcock A, Li H, Lai Y, Brand-Wiita S, Notinger S, Bavle A, Mamtani R.: Cost-effectiveness of enfortumab vedotin plus pembrolizumab as a first-line treatment of locally advanced or metastatic urothelial carcinoma in the United States. J Med Econ Oct 2025.